Our team of experts brings you cancer-related news and research updates.
ACS 2021 studies show how COVID-19 is affecting prevention efforts, expected cancer screening rates, treatment, quality-of-life, and research.
The US Food and Drug Administration (FDA) has approved Lumoxiti (moxetumomab pasudotox-tdfk) for adults with hairy cell leukemia (HCL) that did not get better with at least 2 different previous treatments or got better but then came back.
The US Food and Drug Administration (FDA) has approved a new targeted therapy for a certain type of chronic lymphocytic leukemia (CLL).